Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

被引:419
|
作者
Kasahara, A
Hayashi, N
Mochizuki, K
Takayanagi, M
Yoshioka, K
Kakumu, S
Iijima, A
Urushihara, A
Kiyosawa, K
Okuda, M
Hino, K
Okita, K
机构
[1] Osaka Univ, Sch Med, Dept Med 1, Suita, Osaka 5650871, Japan
[2] Nagoya Univ, Sch Med, Dept Med 3, Nagoya, Aichi 466, Japan
[3] Shinshu Univ, Sch Med, Dept Med 2, Matsumoto, Nagano 390, Japan
[4] Yamaguchi Univ, Sch Med, Dept Med 1, Ube, Yamaguchi 755, Japan
关键词
D O I
10.1002/hep.510270529
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To elucidate the risk factors for liver carcinogenesis and to examine the incidence of hepatocellular carcinoma (HCC) after interferon therapy, 1,022 chronic hepatitis C patients treated with interferon were followed by ultrasonography for 13 to 97 months (median 36 months). Sustained response with prolonged alanine aminotransferase normalization was found in 313 patients, transient response with alanine aminotransferase relapse after therapy in 304, and no response in 405, Forty-six developed HCC, of whom 5 were sustained responders, 9 were transient responders, and 32 were nonresponders. The cumulative incidence of HCC in transient responders was almost equal to that in sustained responders, and it was significantly higher in nonresponders than in sustained and transient responders (P = .0009), The seventh-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders mere estimated to be 4.3%, 4.7%, and 26.1%, respectively. However, there was no significant difference in the cumulative incidence of HCC between patients with HCV subtype 1 and 2 (P = .14). Cox regression analysis showed that the risk of HCC development was not elevated in transient responders compared with sustained responders, but that the risk was 7.90-fold higher in nonresponders than in sustained responders (P = .008), Patients greater than or equal to 55 years of age had a significantly higher risk ratio (4.65) than did those under 55 years of age (P = .006). The risk of HCC development in men was 4.35 times higher than the risk in women (P = .02). However, the degree of fibrosis was not a significant risk factor for the development of HCC (risk ratio, 3.16; P = .052). These results suggest that patients in the high-risk group of HCC after interferon therapy were those who showed no response, those who were older, and those who were male, and that such patients should be carefully followed using ultrasonography.
引用
收藏
页码:1394 / 1402
页数:9
相关论文
共 50 条
  • [41] Liver stiffness and the incidence of hepatocellular carcinoma in patients with chronic hepatitis C
    Nakayama, Yuji
    Takeda, Tadashi
    Yasuda, Takahiro
    Nakaya, Mika
    Nakahara, Kenishi
    Fujii, Hideki
    Kobayashi, Sawako
    Iwai, Shuuji
    Enomoto, Masaru
    Tamori, Akihiro
    Sakaguchi, Hiroki
    Habu, Daiki
    Seki, Shuichi
    Kawada, Nonfumi
    GASTROENTEROLOGY, 2007, 132 (04) : A780 - A780
  • [42] Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
    Kim, In Jung
    Yoo, Sung Hwan
    Kim, Sora
    Cho, Young Youn
    Yoo, Ki Young
    Kim, Hyung Joon
    Lee, Hyun Woong
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
  • [43] Interferon treatment prolongs survival and reduces risk of hepatocellular carcinoma in chronic hepatitis C and cirrosis.
    Nishiguchi, S
    Nakatani, S
    Minamitani, S
    Fukuda, K
    Takeda, T
    Nakajima, S
    Shiomi, S
    Seki, S
    Kuroki, T
    HEPATOLOGY, 1997, 26 (04) : 1144 - 1144
  • [44] Incidence and risk factors of hepatocellular carcinoma in chronic hepatitis C: Results of a prospective cohort study.
    Niederau, C
    Lange, S
    Erhardt, A
    Heintges, T
    Buschkamp, M
    Hurter, D
    Rohlen, M
    Hensel, F
    Wenning, M
    Petry, W
    Niederau, CM
    Haussinger, D
    HEPATOLOGY, 1997, 26 (04) : 230 - 230
  • [45] Erythropoietin use in patients on chronic hepatitis C treatment: Incidence of thromboembolic events and hepatocellular carcinoma
    Werner, Kristina T.
    Rosati, Marianne J.
    Vargas, Hugo E.
    Byrne, Thomas
    Rakela, Jorge L.
    GASTROENTEROLOGY, 2008, 134 (04) : A843 - A843
  • [46] Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C
    Miyake, Yasuhiro
    Iwasaki, Yoshiaki
    Yamamoto, Kazuhide
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (04) : 989 - 996
  • [47] The incidence of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virological response to interferon therapy
    Kobayashi, S.
    Enomoto, M.
    Tamori, A.
    Kawada, N.
    Habu, D.
    Sakaguchi, H.
    Takedal, T.
    Nishiguchi, S.
    Seki, S.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S219 - S219
  • [48] Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders
    Imai, Y.
    Tamura, S.
    Tanaka, H.
    Hiramatsu, N.
    Kiso, S.
    Doi, Y.
    Inada, M.
    Nagase, T.
    Kitada, T.
    Imanaka, K.
    Fukuda, K.
    Takehara, T.
    Kasahara, A.
    Hayashi, N.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 (03) : 185 - 191
  • [49] Hepatic iron accumulation is an independent risk factor for the development of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C
    Izumi, N
    Asahina, Y
    Uchihara, M
    Osamu, N
    Kanazawa, N
    Itakura, J
    Miyake, S
    Sakai, T
    GASTROENTEROLOGY, 2001, 120 (05) : A77 - A77
  • [50] New Scoring Method to Predict Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C After Pegylated Interferon and Ribavirin Therapy
    Hu, Ching-Chih
    Weng, Cheng-Hao
    Hua, Man-Chin
    Chang, Pei-Hung
    Lin, Chih-Lang
    Chen, Yen-Ting
    Chien, Cheng-Hung
    Lin, Shu-Ting
    Chien, Rong-Nan
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2020, 40 (02): : 82 - 91